$75.3 Million is the total value of Qiming U.S. Ventures Management, LLC's 7 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ICOSAVAX INC | $27,204,267 | -22.0% | 3,510,228 | 0.0% | 36.12% | -1.4% | ||
| Sell | VENTYX BIOSCIENCES INC | $23,837,630 | -2.6% | 686,370 | -8.0% | 31.65% | +23.0% | |
| TALS | TALARIS THERAPEUTICS INC | $8,240,623 | -7.6% | 2,932,606 | 0.0% | 10.94% | +16.8% | |
| HILLEVAX INC | $7,517,514 | -21.8% | 558,923 | 0.0% | 9.98% | -1.1% | ||
| JASPER THERAPEUTICS INC | $5,963,754 | -48.9% | 8,519,648 | 0.0% | 7.92% | -35.4% | ||
| ELEV | ELEVATION ONCOLOGY INC | $1,570,456 | -56.4% | 2,370,142 | 0.0% | 2.08% | -44.9% | |
| KZR | KEZAR LIFE SCIENCES INC | $986,166 | -51.4% | 828,711 | 0.0% | 1.31% | -38.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICOSAVAX INC | 8 | Q3 2023 | 37.0% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 37.8% |
| TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
| JASPER THERAPEUTICS INC | 8 | Q3 2023 | 21.1% |
| KEZAR LIFE SCIENCES INC | 8 | Q3 2023 | 12.9% |
| ELEVATION ONCOLOGY INC | 8 | Q3 2023 | 6.6% |
| HILLEVAX INC | 6 | Q3 2023 | 13.9% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-24 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-07-22 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.